Obesity: Competitive Landscape to 2026

Publisher Name :
Date: 31-Oct-2018
No. of pages: 50

Obesity: Competitive Landscape to 2026

Summary

Obesity is a preventable chronic condition, defined as abnormal or excessive fat accumulation characterized by raised body mass index (BMI ?30), which is a major risk factor for chronic diseases such as cardiovascular diseases (CVD), diabetes, musculoskeletal disorders, and several major cancers.

This report provides an assessment of the pipeline, clinical, and commercial landscape of Obesity. Overall, GlobalData expects that the approval of new long-acting GLP-1R and dual GLP-1R/GCGR agonists, and a novel appetite reducing drug will drive Obesity market growth during the next decade.

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -

- Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type

- Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics

- Commercial Assessment: leading marketed products, current and future players

- Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Obesity market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Obesity market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Obesity: Competitive Landscape to 2026

Table of Contents
1. Preface 2
1.1 Table of Contents 2
1.2 Abbreviations 3
1.3 Related Reports 4
2. Executive Summary 5
2.1 Key Findings 6
2.2 Key Events 7
3. Introduction 8
3.1 Report Scope 9
3.2 Disease Overview and Epidemiology 11
4. Pipeline Assessment 13
4.1 Pipeline Overview 14
4.2 Pipeline Breakdown by Region/Country 16
4.3 Pipeline Breakdown by Molecule Type and Target 17
4.4 Drug Review Designations 18
4.5 Products in Clinical Development 19
5. Clinical Trial Assessment 21
5.1 Clinical Trials Overview 22
5.2 Top Sponsors of Clinical Trials in Obesity 23
5.3 Trial Breakdown by Region 25
5.4 Therapy Area Perspective 26
5.5 Enrollment Analytics 27
6 Commercial Assessment 30
6.1 Leading Marketed Products 31
6.2 Current & Future Players 32
7. Competitive Landscape Analysis (2016-2026) 33
7.1 Events Classification Overview 34
7.2 US 35
7.3 5EU 36
7.4 Japan 37
7.5 China 38
8 Appendix 39
8.1 Sources 40
8.2 Methodology 42
8.3 Key Events Included in the Analysis 43
8.4 About the Authors 45
8.5 About GlobalData 48
8.6 Disclaimer 50
  • Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020
    Published: 12-Mar-2020        Price: US 2500 Onwards        Pages: 388
    Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Pre-Diabetes Impaired Glucose Tolerance Global Clinical Trials Review, H1, 2020" provides an overview of Pre-Diabetes Impaired Glucose Tolerance Clinical trials scenario. This report provides top line data relating to the clinical trials on Pre-Diabetes Impaired Glucose Tolerance. Report includes an overview of trial numbers and their average enro......
  • Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H1, 2020
    Published: 09-Mar-2020        Price: US 2500 Onwards        Pages: 1094
    Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Type 1 Diabetes (Juvenile Diabetes) Global Clinical Trials Review, H1, 2020" provides an overview of Type 1 Diabetes (Juvenile Diabetes) Clinical trials scenario. This report provides top line data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes). Report includes an overview of trial numbers and their average enrollment in top co......
  • Diabetic Nephropathy Global Clinical Trials Review, H1, 2020
    Published: 09-Mar-2020        Price: US 2500 Onwards        Pages: 404
    Diabetic Nephropathy Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Diabetic Nephropathy Global Clinical Trials Review, H1, 2020" provides an overview of Diabetic Nephropathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Nephropathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers covera......
  • Diabetic Macular Edema Global Clinical Trials Review, H1, 2020
    Published: 06-Mar-2020        Price: US 2500 Onwards        Pages: 421
    Diabetic Macular Edema Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Diabetic Macular Edema Global Clinical Trials Review, H1, 2020" provides an overview of Diabetic Macular Edema Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Macular Edema. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offer......
  • Dyslipidemia - Pipeline Review, H1 2020
    Published: 01-Mar-2020        Price: US 2000 Onwards        Pages: 372
    Dyslipidemia - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyslipidemia - Pipeline Review, H1 2020, provides an overview of the Dyslipidemia (Metabolic Disorders) pipeline landscape. Dyslipidemia is defined as elevation of the total cholesterol, the "bad" low-density lipoprotein (LDL) cholesterol and the triglyceride concentrations, and a decrease in the "good" high-density lipoprotein......
  • Diabetic Nephropathy - Pipeline Review, H1 2020
    Published: 28-Feb-2020        Price: US 2000 Onwards        Pages: 264
    Diabetic Nephropathy - Pipeline Review, H1 2020 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Pipeline Review, H1 2020, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape. Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk......
  • Peptide Therapeutics in Metabolic Disorder Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 09-Feb-2020        Price: US 3000 Onwards        Pages: 142
    Peptide Therapeutics in Metabolic Disorder Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Peptide Therapeutics in Metabolic Disorder industry with a focus on the Chinese market. The report provides key statistics on the market status of the Peptide Therapeutics in Metabolic Disorder manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the repor......
  • Hyperglycemia Global Clinical Trials Review, H1, 2020
    Published: 01-Feb-2020        Price: US 2500 Onwards        Pages: 242
    Hyperglycemia Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Hyperglycemia Global Clinical Trials Review, H1, 2020" provides an overview of Hyperglycemia Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperglycemia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trial......
  • Diabetic Retinopathy Global Clinical Trials Review, H1, 2020
    Published: 01-Feb-2020        Price: US 2500 Onwards        Pages: 330
    Diabetic Retinopathy Global Clinical Trials Review, H1, 2020 Summary GlobalData's clinical trial report, "Diabetic Retinopathy Global Clinical Trials Review, H1, 2020" provides an overview of Diabetic Retinopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Diabetic Retinopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers covera......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs